APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vascular Endothelial Growth Factor (VEGF) Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Outlook and Growth Opportunities 2026

Report ID 174045280422 December 2025194 pages

Choose your research edition.

Industry ResearchVascular Endothelial Growth Factor (VEGF) Inhibitors Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Vascular Endothelial Growth Factor (VEGF) Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Vascular Endothelial Growth Factor (VEGF) Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vascular Endothelial Growth Factor (VEGF) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vascular Endothelial Growth Factor (VEGF) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vascular Endothelial Growth Factor (VEGF) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vascular Endothelial Growth Factor (VEGF) Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vascular Endothelial Growth Factor (VEGF) Inhibitors market include Sanofi., Novartis AG, Bayer AG, Regeneron Pharmaceuticals Inc. and F. Hoffmann-La Roche Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Vascular Endothelial Growth Factor (VEGF) Inhibitors market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vascular Endothelial Growth Factor (VEGF) Inhibitors and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vascular Endothelial Growth Factor (VEGF) Inhibitors revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Vascular Endothelial Growth Factor (VEGF) Inhibitors market.

Vascular Endothelial Growth Factor (VEGF) Inhibitors Segment by Company

Sanofi.

Novartis AG

Bayer AG

Regeneron Pharmaceuticals Inc.

F. Hoffmann-La Roche Ltd.

Vascular Endothelial Growth Factor (VEGF) Inhibitors Segment by Type

VEGF-D Inhibitor

VEGF-C Inhibitor

VEGF-B Inhibitor

VEGF-A Inhibitor

Vascular Endothelial Growth Factor (VEGF) Inhibitors Segment by Application

Oncology

Ophthalmology

Vascular Endothelial Growth Factor (VEGF) Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Vascular Endothelial Growth Factor (VEGF) Inhibitors status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Vascular Endothelial Growth Factor (VEGF) Inhibitors key companies, revenue, market share, and recent developments.

3. To split the Vascular Endothelial Growth Factor (VEGF) Inhibitors breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Vascular Endothelial Growth Factor (VEGF) Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vascular Endothelial Growth Factor (VEGF) Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze Vascular Endothelial Growth Factor (VEGF) Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vascular Endothelial Growth Factor (VEGF) Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vascular Endothelial Growth Factor (VEGF) Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vascular Endothelial Growth Factor (VEGF) Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vascular Endothelial Growth Factor (VEGF) Inhibitors industry.

Chapter 3: Detailed analysis of Vascular Endothelial Growth Factor (VEGF) Inhibitors company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Vascular Endothelial Growth Factor (VEGF) Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Vascular Endothelial Growth Factor (VEGF) Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Trends Table 2. Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Drivers Table 3. Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Opportunities and Challenges Table 4. Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Restraints Table 5. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Company (2021-2026) Table 7. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Key Company Manufacturing Base & Headquarters Table 9. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Company, Product Type & Application Table 10. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of VEGF-D Inhibitor Table 15. Significant Companies of VEGF-C Inhibitor Table 16. Significant Companies of VEGF-B Inhibitor Table 17. Significant Companies of VEGF-A Inhibitor Table 18. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type (2021-2026) Table 22. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Oncology Table 24. Significant Companies of Ophthalmology Table 25. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application (2021-2026) Table 29. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application (2027-2032) Table 30. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Region (2021-2026) Table 33. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Region (2027-2032) Table 35. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Market Share by Country (2021-2026) Table 38. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Market Share by Country (2027-2032) Table 40. Sanofi. Company Information Table 41. Sanofi. Business Overview Table 42. Sanofi. Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Sanofi. Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio Table 44. Sanofi. Recent Development Table 45. Novartis AG Company Information Table 46. Novartis AG Business Overview Table 47. Novartis AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Novartis AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio Table 49. Novartis AG Recent Development Table 50. Bayer AG Company Information Table 51. Bayer AG Business Overview Table 52. Bayer AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Bayer AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio Table 54. Bayer AG Recent Development Table 55. Regeneron Pharmaceuticals Inc. Company Information Table 56. Regeneron Pharmaceuticals Inc. Business Overview Table 57. Regeneron Pharmaceuticals Inc. Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Regeneron Pharmaceuticals Inc. Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio Table 59. Regeneron Pharmaceuticals Inc. Recent Development Table 60. F. Hoffmann-La Roche Ltd. Company Information Table 61. F. Hoffmann-La Roche Ltd. Business Overview Table 62. F. Hoffmann-La Roche Ltd. Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. F. Hoffmann-La Roche Ltd. Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio Table 64. F. Hoffmann-La Roche Ltd. Recent Development Table 65. Research Programs/Design for This Report Table 66. Authors List of This Report Table 67. Secondary Sources Table 68. Primary Sources List of Figures Figure 1. Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Image Figure 2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. VEGF-D Inhibitor Image Figure 8. VEGF-C Inhibitor Image Figure 9. VEGF-B Inhibitor Image Figure 10. VEGF-A Inhibitor Image Figure 11. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type (2021-2032) Figure 14. Oncology Image Figure 15. Ophthalmology Image Figure 16. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application (2021-2032) Figure 19. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 22. North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 28. South America Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • VEGF-D Inhibitor
  • VEGF-C Inhibitor
  • VEGF-B Inhibitor
  • VEGF-A Inhibitor
Applications
  • Oncology
  • Ophthalmology
Companies covered
  • Sanofi.
  • Novartis AG
  • Bayer AG
  • Regeneron Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Dynamics
  1. 2.1 Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Trends
  2. 2.2 Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Drivers
  3. 2.3 Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Opportunities and Challenges
  4. 2.4 Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Restraints
3 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market by Company
  1. 3.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Company Ranking (2024-2026)
  4. 3.4 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Company Manufacturing Base and Headquarters
  5. 3.5 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Company Product Type and Application
  6. 3.6 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Vascular Endothelial Growth Factor (VEGF) Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market by Type
  1. 4.1 Vascular Endothelial Growth Factor (VEGF) Inhibitors Type Introduction
  2. 4.1.1 VEGF-D Inhibitor
  3. 4.1.2 VEGF-C Inhibitor
  4. 4.1.3 VEGF-B Inhibitor
  5. 4.1.4 VEGF-A Inhibitor
  6. 4.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Type
  7. 4.2.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Type (2021-2032)
  9. 4.2.3 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type (2021-2032)
5 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market by Application
  1. 5.1 Vascular Endothelial Growth Factor (VEGF) Inhibitors Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Ophthalmology
  4. 5.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Application
  5. 5.2.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Application (2021-2032)
  7. 5.2.3 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application (2021-2032)
6 Vascular Endothelial Growth Factor (VEGF) Inhibitors Regional Value Analysis
  1. 6.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Region (2021-2032)
  3. 6.2.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Region: 2021-2026
  4. 6.2.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value (2021-2032)
  7. 6.3.2 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value (2021-2032)
  10. 6.4.2 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value (2021-2032)
  16. 6.6.2 South America Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Country, 2025 VS 2032
7 Vascular Endothelial Growth Factor (VEGF) Inhibitors Country-level Value Analysis
  1. 7.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Country (2021-2032)
  3. 7.2.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Country (2021-2026)
  4. 7.2.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Vascular Endothelial Growth Factor (VEGF) Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi.
  2. 8.1.1 Sanofi. Company Information
  3. 8.1.2 Sanofi. Business Overview
  4. 8.1.3 Sanofi. Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi. Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio
  6. 8.1.5 Sanofi. Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Bayer AG
  14. 8.3.1 Bayer AG Company Information
  15. 8.3.2 Bayer AG Business Overview
  16. 8.3.3 Bayer AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio
  18. 8.3.5 Bayer AG Recent Developments
  19. 8.4 Regeneron Pharmaceuticals Inc.
  20. 8.4.1 Regeneron Pharmaceuticals Inc. Company Information
  21. 8.4.2 Regeneron Pharmaceuticals Inc. Business Overview
  22. 8.4.3 Regeneron Pharmaceuticals Inc. Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Regeneron Pharmaceuticals Inc. Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio
  24. 8.4.5 Regeneron Pharmaceuticals Inc. Recent Developments
  25. 8.5 F. Hoffmann-La Roche Ltd.
  26. 8.5.1 F. Hoffmann-La Roche Ltd. Company Information
  27. 8.5.2 F. Hoffmann-La Roche Ltd. Business Overview
  28. 8.5.3 F. Hoffmann-La Roche Ltd. Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue and Gross Margin (2021-2026)
  29. 8.5.4 F. Hoffmann-La Roche Ltd. Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio
  30. 8.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst